TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05886777

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Placebo
Description: Normal saline (0.9% sodium chloride solution for injection)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Placebo
Description: Normal saline (0.9% sodium chloride solution for injection)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Normal Saline Placebo
Description: Normal saline (0.9% sodium chloride solution for injection)
Study: NCT06145750

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ability to order FirstLook™
Description: FirstLook™ is a commercially available, validated next generation sequencing assay of plasma cell-free DNA (cfDNA) that analyzes the distribution of cfDNA fragment sizes to indicate the presence of possible lung cancer. FirstLook™ is intended to be used by a qualified healthcare provider and is not a replacement for computed tomography (CT) or low-dose computed tomography (LDCT). FirstLook™ is validated for use in individuals aged 50 or older who either currently or previously smoked cigarettes and accumulated 20 pack-years or more of exposure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuing Medical Education for Lung Cancer
Description: Physician practice will receive standard education on lung cancer screening for CME credit.
Study: NCT05675709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training and Education
Description: Undergo group trainings
Study: NCT05934188

Intervention type: BEHAVIORAL
Intervention: Eating habits
Description: Information on eating habits will be derived from food questionnaires.

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome analyses
Description: The Microbiome analyses will be derived from a stool sample (16S rRNA sequencing targeted metagenomic analyses).

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome analyses
Description: The Microbiome analyses will be derived from a stool sample (16S rRNA sequencing targeted metagenomic analyses).

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome analyses
Description: The Microbiome analyses will be derived from a stool sample (16S rRNA sequencing targeted metagenomic analyses).

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome analyses
Description: The Microbiome analyses will be derived from a stool sample (16S rRNA sequencing targeted metagenomic analyses).

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome analyses
Description: The Microbiome analyses will be derived from a stool sample (16S rRNA sequencing targeted metagenomic analyses).

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory markers
Description: Inflammatory markers will be evaluated in terms RNA expression level in plasma blood sample.

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory markers
Description: Inflammatory markers will be evaluated in terms RNA expression level in plasma blood sample.

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory markers
Description: Inflammatory markers will be evaluated in terms RNA expression level in plasma blood sample.

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory markers
Description: Inflammatory markers will be evaluated in terms RNA expression level in plasma blood sample.

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory markers
Description: Inflammatory markers will be evaluated in terms RNA expression level in plasma blood sample.

Intervention type: DIAGNOSTIC_TEST
Intervention: Alzheimer's Disease biomarkers
Description: The Alzheimer's Disease biomarkers will be measured in the plasma of prodromal Alzheimer's Disease patients.
Study: NCT06484205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WHO QualityRights e-training
Description: WHO QualityRights training provides the necessary skills to support people with psychosocial disabilities in advocating for their rights. The QualityRights online course includes six main modules: 1) Human Rights; 2) Human rights, mental health and disability; 3) Legal capacity and the right to decide; 4) Stop coercion, violence and mistreatment; 5) Quality services and inclusion in the community; 6) Mental health, well-being and recovery and it will take approximately 8 hours for completion. QualityRights course modules can be completed at each participant's pace and needs. The training is considered concluded once the quizzes provided at the end of each of the six modules have been successfully completed and upon completion of the course it will be possible to download your official WHO certificate from the QR platform.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emotional intelligence e-training
Description: This course offers caregivers resources and knowledge so that they are able to manage their emotions and gain quality in the care they provide to others and in their own lives. The course duration is similar to that of the QualityRights online course and is intended for caregivers of people with disabilities and others interested
Study: NCT06522984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: to evaluate and compare efficacy of:~* Fractional Er: YAG laser combined with topical hydroquinone.~* Intradermal injection of tranexamic acid combined with topical hydroquinone cream.~* Oral administration of tranexamic acid combined with topical hydroquinone cream. In treating refractory melasma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: to evaluate and compare efficacy of:~* Fractional Er: YAG laser combined with topical hydroquinone.~* Intradermal injection of tranexamic acid combined with topical hydroquinone cream.~* Oral administration of tranexamic acid combined with topical hydroquinone cream. In treating refractory melasma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: to evaluate and compare efficacy of:~* Fractional Er: YAG laser combined with topical hydroquinone.~* Intradermal injection of tranexamic acid combined with topical hydroquinone cream.~* Oral administration of tranexamic acid combined with topical hydroquinone cream. In treating refractory melasma.
Study: NCT06187038

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercises
Description: The therapeutic exercise program will include warm-up, resistance, neuromuscular, mobility, and balance exercises. Over ten weeks, two sessions of the therapeutic exercise program will be carried out individually, lasting approximately 60 minutes each-a total of 20 therapeutic exercise sessions. Therapeutic exercise sessions will be carried out at least 24 hours between sessions. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises
Description: The therapeutic exercise program will include warm-up, resistance, neuromuscular, mobility, and balance exercises. Over ten weeks, two sessions of the therapeutic exercise program will be carried out individually, lasting approximately 60 minutes each-a total of 20 therapeutic exercise sessions. Therapeutic exercise sessions will be carried out at least 24 hours between sessions. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
Study: NCT05168930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: C4-15
Study: NCT06187038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises + pain neuroscience education program
Description: In addition to the therapeutic exercise protocol previously reported in the control group, research participants allocated to the experimental group will undergo an education program in the neurosciences of chronic pain carried out one day a week between the two therapeutic exercise sessions lasting ten weeks.~The chronic pain neuroscience education program will be based on three domains. Making sense of pain, Exposure with control, and Lifestyle changes also urge modifications aimed at improving sleep, stress, and anxiety.
Study: NCT05542381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate Ophthalmic Gel [Lotemax]
Description: Loteprednol (ophthalmic corticosteroid) will be stored in the clinic according to the instructions on the package. The vial will be stored upright between 15°-25°C (59°-77°F). In the clinic, the vial will be opened by the retina surgeon according to sterile procedure and administered (1 drop) by the surgeon immediately after the intravitreal injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Refresh Lubricant Eye Drops [Artificial Tears]
Description: REFRESH® Brand Lubricant Eye Drops are artificial tears. In the clinic, the vial will be opened by the retina surgeon according to sterile procedure and administered (1 drop) by the surgeon immediately after the intravitreal injection.
Study: NCT06275932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional group
Description: Newborns will be covered with a thermal blanket during skin-to-skin contact in delivery room.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care group
Description: Newborns will be covered with a bed wetting mat and cotton sheet during skin-to-skin contact in delivery room.
Study: NCT05168930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: C4-15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: C4-15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: C1-15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: C1-15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: C1-15
Study: NCT06282692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 µg
Description: Dose : 1 dose 0.5 ml containing 5 µg inactivated SARS-CoV-2 virus, Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride.
Study: NCT05045066

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05650554

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza mRNA Vaccine MRT5413
Description: Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza mRNA Vaccine MRT5413
Description: Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza mRNA Vaccine MRT5413
Description: Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Recombinant Influenza Vaccine
Description: Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Influenza Standard Dose Vaccine
Description: Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Influenza High-Dose Vaccine
Description: Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection
Study: NCT06224751

Intervention type: DIAGNOSTIC_TEST
Intervention: Near logMAR letter acuity
Description: Comparison of gold standard printed tests and computerised versions

Intervention type: DIAGNOSTIC_TEST
Intervention: Near LogMAR word acuity
Description: Comparison of gold standard printed tests and computerised versions

Intervention type: DIAGNOSTIC_TEST
Intervention: Red Green Stereoacuity
Description: Comparison of gold standard printed tests and computerised versions

Intervention type: DIAGNOSTIC_TEST
Intervention: Auckland Optotype/Auckland Vanishing Optotypes
Description: Comparison of gold standard printed tests and computerised versions

Intervention type: DIAGNOSTIC_TEST
Intervention: Vanishing Optotype Sloan Letters
Description: Comparison of gold standard printed tests and computerised versions

Intervention type: DIAGNOSTIC_TEST
Intervention: Letter Contrast Sensitivity
Description: Comparison of gold standard printed tests and computerised versions

Intervention type: DIAGNOSTIC_TEST
Intervention: Low Contrast Letter Acuity
Description: Comparison of gold standard printed tests and computerised versions
Study: NCT05313217

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Knee extension angle
Description: Knee Extension Angle (KEA):~* This test will be administered with an ankle-foot orthosis (AFO) maintaining the participants ankle in neutral.~* The participant will lie supine on the examination table with the contralateral lower extremity (LE) stabilized on the support surface using a mobilization strap.~* The hip of the lower being examined will be flexed to 90 degrees.~* The participant will then actively straighten their lower leg while maintaining upper leg in same position~* Once the participant feels they are at maximal knee extension (patient instructed to straighten leg as far as what is comfortable), the angle will be measured with iPhone Inclinometer.~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Straight Leg Raise
Description: Straight Leg Raise (SLR):~* Position the participant in supine on the plinth with knees extended and L LE strapped to the plinth~* The participant will keep the AFO donned on the R distal ankle to keep the ankle in neutral position.~* A researcher will passively lift the participant's right leg moving at a slow but consistent pace of approximately 15 degrees per second, while keeping it straight until a significant resistance is detected or the participant reports a production of symptoms, whichever occurs first.~* Measurement of the SLR angle will be assessed with iPhone inclinometer.~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Slump Test
Description: Slump Test Procedure:~* Participant will be instructed to sit upright with their legs over the edge of table~* AFO remains on R leg~* Participant will sequentially flex trunk, look down at the floor~* Participant will extend R knee until symptoms are felt. Measure of angle with iPhone inclinometer placed at superior aspect of medial malleolus~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Extended slump test
Description: Extended Slump Procedure:~* Participant will be instructed to sit upright with their legs over the edge of table~* AFO remains on R leg~* Participant is asked to arch their lower back into maximal extension in sitting, stabilized to research bench to maintain hyper-lordosis posture.~* The participant is asked first flex cervical spine, then to extend their knee until it reaches full ROM or symptoms are felt that limit ROM.~* Knee extension ROM is assessed with iPhone inclinometer at superior aspect of medial malleolus.~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)
Study: NCT04811794

Intervention type: OTHER
Intervention: Physical examination, diagnostic tests, laboratory tests
Description: Physical examination, diagnostic tests (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels) depend on examined organ system.

Intervention type: OTHER
Intervention: Physical examination, diagnostic tests, laboratory tests
Description: Physical examination, diagnostic tests (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels) depend on examined organ system.

Intervention type: OTHER
Intervention: Personal history
Description: Personal history on diagnosis, treatment, and socioeconomic factors

Intervention type: OTHER
Intervention: Personal history
Description: Personal history on diagnosis, treatment, and socioeconomic factors
Study: NCT04215510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endonasal endoscopic surgery
Description: 143 patients will undergo endonasal endoscopic surgery

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy(IMRT)
Description: 143 patients will undergo radiation therapy.
Study: NCT04887818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Diltiazem ointment with 1.5% lidocaine
Description: 3 g of topical 2% diltiazem ointment with 1.5 % lidocaine applied in the perianal region circumferential q12h x 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% Nifedipine ointment with 1.5% lidocaine
Description: 3 g of topical 0.3% nifedipine ointment with 1.5 % lidocaine applied in the perianal region circumferential q12h x 12 weeks
Study: NCT04489589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: 10mg PO/NG q8h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg PO/NG q8h
Study: NCT05348889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1A46 Injection
Description: Participants will receive IV 1A46 weekly for Cycles 1-8, then every 3 weeks (Q3W) for Cycles 9-16 (21 days/cycle).
Study: NCT01393587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Taking blood samples
Study: NCT05793567

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary angiogram with coronary reactivity testing (CRT)
Description: CRT is an angiography procedure (using X-ray) to examine the small blood vessels in the heart and how they respond to three drugs (adenosine, acetylcholine and nitroglycerin) as per clinical protocol.
Study: NCT05293288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG-guided general anesthesia
Description: pEEG monitoring will start with the beginning of induction of general anesthesia and will end with the end of surgery (surgical suture). In the EEG-guided group, depth of anesthesia will be adjusted to target PSI values between 25 and 50 and spectral edge frequency between 10 and 15. In case of contradictory values, the raw EEG waveforms, ARTF, EMG, as well as the overall clinical situation will be evaluated for decision making.
Study: NCT05700214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: 30ml of 0.375% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 1 mg/kg IBW i.v.
Study: NCT05297916

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enteral feeding
Description: to intake oral feeding or delay it

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enteral feeding
Description: to intake oral feeding or delay it
Study: NCT06429358

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus
Description: The probiotic supplement was delivered in the form of easy-to-swallow capsules.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Participants in the control group were given a placebo that looked, tasted, and felt just like the probiotic pill.
Study: NCT06147622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin + cyproheptadine
Description: Subjects will receive prazosin + cyproheptadine on day 1 of period 1 or on day 1 of period 2 depending on randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT110
Description: Subjects will receive KT110 on day 1 of period 1 or on day 1 of period 2 depending on randomization.
Study: NCT05249634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jatenzo Pill
Description: oral tablet daily
Study: NCT04829981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAFEWATER systems for drinking water disinfection
Description: A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change interventions
Description: Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
Study: NCT05720754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diquafosol tetrasodium
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diquafosol tetrasodium
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated eye mask
Description: Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated eye mask
Description: Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
Study: NCT05413577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: The intervention recordings taught the basic concepts of mindfulness through simple guided meditations with content supported by science. Each recording had the same format that included (1) a daily theme, (2) a meditation exercise echoing the theme, (3) a suggested exercise for practice, and (4) an invitation for participants to give a short response to their meditation experience at the end of the recording.
Study: NCT05753397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: We are testing if single injection Ropivacaine is non-inferior to multiple-injection Ropivacaine when applied within the intertransverse tissue complex (that is: a paraspinal application mimicking the paravertebral block)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: We are testing if single injection Ropivacaine is non-inferior to multiple-injection Ropivacaine when applied within the intertransverse tissue complex (that is: a paraspinal application mimicking the paravertebral block)